Vertigo Treatment Market Research Report - Forecast till 2030

Vertigo Treatment Market Research Report: By Type (BPPV, Labyrinthitis, Vestibular Neuronitis, Meniere’s disease), By Treatment (Anticholinergics, Antihistamines, Benzodiazepines, Others) and By End-User (Hospital, Clinics)-Forecast to 2030

ID: MRFR/HC/6986-HCR | 100 Pages | Published By Kinjoll Dey on March 2023         

Vertigo Treatment Market Speak to Analyst Request a Free Sample

Vertigo Treatment Market

Vertigo Treatment Market accounted for USD 2150 Million at a CAGR of 4.80% during forecast period

By Type BPPV Labyrinthitis Vestibular Neuronitis Meniere&rsquo disease
By Treatment Anticholinergics Antihistamines Benzodiazepines Others
By End-User Hospital Clinics
Key Players
Companies Profiled   Hoffmann-La Roche (Switzerland)   GlaxoSmithKline (UK)   Novartis (Switzerland)   Pfizer (US)   Teva Pharmaceutical (Israel)   Sanofi (France)   AstraZeneca (UK)   Intas Pharmaceutical Ltd (India)   Sun Pharmaceutical Industries Ltd (India)
Market Driving Forces   Increase in prevalence of vertigo cases   Rise in healthcare expenditure   Increasing geriatric population
Request a Free Sample

Vertigo Treatment Market Forecast

The vertigo treatment market is anticipated to reach USD 2150 Million by 2030 at 4.80% CAGR during the forecast period 2022-2030

Market Synopsis

Vertigo is a sense of spinning dizziness that can be caused by problems in the brain or inner ear, including sudden head movements, or inflammation in the inner ear due to a viral or bacterial infection. Vertigo can be treated with medications such as steroids that can reduce internal ear inflammation, and water pills that can reduce fluid buildup in the ear.

Vertigo Treatment Market Influencer

The increasing initiatives by public and private companies influence the market growth positively. The ever-increasing number of clearances and product launches by key players in the market are likely to act as a promising factor for the vertigo teatment market growth in the near future.

Vertigo Treatment Market Drivers

  • Increase in prevalence of vertigo cases

    • Cases of vertigo are on the rise, with over 20% 50% of the global population affected by vertigo and According to the National Center for Biotechnology Information, in the US, around 26 million people required a visit to an emergency department for dizziness/vertigo.

  • Rapid technological advancements

  • Rise in healthcare expenditure

  • Increasing geriatric population

  • Increasing mergers & acquisitions by prominent players in the vertigo treatment market

  • Growing initiatives to create awareness

    • For instance, the German Center for Vertigo and Balance Disorders (DSGZ) started an initiative called DIZZYNET. The main aim is to create a platform for collaboration and exchange among scientists, physicians, and physiotherapists to understand the treatment options and epidemiology of vertigo. Such initiates help to create awareness regarding symptoms and treatment for vertigo.

Vertigo Treatment Market Restraints

  • Lack of information about the symptoms and causes of vertigo

Vertigo Treatment Market Segmentation

By Type

  • Benign Paroxysmal Positional Vertigo (BPPV): Expected to hold the largest share, as benign paroxysmal positional vertigo is the most common form of peripheral vertigo. This type tends to cause short, frequent bouts of vertigo.

  • Labyrinthitis: An inner ear infection causes labyrinthitis form of vertigo. This form of vertigo is usually overlooked as they appear with other symptoms such as fever and earache.

  • Vestibular Neuronitis: Vestibular neuritis is a disorder that affects the nerve of the inner ear. This type of vertigo has a sudden onset and may cause unsteadiness, earache, nausea, and vomiting.

  • Meniere’s disease: This type of vertigo is often so severe that it causes nausea and vomiting. Meniere’s disease also causes hearing loss, ringing in your ears, and a feeling of fullness in your ears.

By Treatment

  • Anticholinergics: Anticholinergics are vestibular suppressants and are most important in treating vertigo since anticholinergic drugs that do not cross the blood-brain barrier are ineffective in controlling motion sickness. The most effective single anticholinergic drug for the prophylaxis and treatment of motion sickness is scopolamine. All anticholinergics conventionally used in the management of vertigo or motion sickness have prominent side-effects, often including dry mouth, dilated pupils, and sedation. Anticholinergics are ineffective if administered after symptoms have already appeared.

  • Antihistamines: Centrally acting antihistamines prevent motion sickness and reduce the severity of symptoms, even if taken after the onset of the symptoms. All the antihistamines in general use for control of vertigo also have anticholinergic activity.

  • Benzodiazepines: Benzodiazepines are extremely useful for the management of acute vertigo. They are also helpful in controlling motion sickness and can also minimize anxiety and panic associated with vertigo. Diazepam, clonazepam, lorazepam, and alprazolam are commonly prescribed benzodiazepines for their effect as anxiolytics and antidepressants.

  • Others: The other segment includes antibiotics and other drugs that can help ease the symptoms of vertigo.

By End-User

  • Hospital: Hospitals dominate the global market for vertigo treatment. The positive growth of hospitals is attributed to their rising need to offer treatments for various health disorders. Additionally, the large number of hospitals is also driving the growth for the hospital's segment.

  • Clinics: Clinics take up the second-largest share due to the rising number of clinics and the increasing patient population.

Vertigo Treatment Market By Region

  • Americas: It is the largest regional vertigo treatment market owing to the large patient population, rise in prevalence of vertigo, and surge in awareness about the causes of vertigo and its treatments. According to the American Speech-Language-Hearing Association, around 40% of the population in the US experience some form of dizziness or balance difficulty over the course of a lifetime.

  • Europe: The growing presence of the developed pharmaceutical industry and the significant demand for vertigo related therapeutics is driving the growth of the vertigo treatment market in Europe. According to the National Center for Biotechnology Information, the prevalence of vertigo in Germany was 22.9%.

  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global vertigo treatment market. This region has witnessed a surge in the number of people afflicted with vertigo and other neurological disorders.

  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.

Vertigo Treatment Market Key Players

  • Hoffmann-La Roche (Switzerland)

  • GlaxoSmithKline (UK)

  • Novartis (Switzerland)

  • Pfizer (US)

  • Teva Pharmaceutical (Israel)

  • Sanofi (France)

  • AstraZeneca (UK)

  • Intas Pharmaceutical Ltd (India)

  • Sun Pharmaceutical Industries Ltd (India)

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

vertigo treatment market is projected grow at approximately 4.80% CAGR during the assessment period (2022-2030).

The valuation of the global vertigo treatment market had reached 1,800 MN in 2018.

By type, the benign paroxysmal positional vertigo (BPPV) segment, by treatment, the anticholinergics segment, and end user, the hospital segment holds the majority shares in the global vertigo treatment market.

North America holds the largest share in the global vertigo treatment market, followed by Europe and the Asia Pacific, respectively.

GlaxoSmithKline (UK), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), Teva Pharmaceutical (Israel), Pfizer (US), Sanofi (France), Intas Pharmaceutical Ltd (India), AstraZeneca (UK), and Sun Pharmaceutical Industries Ltd (India), are some of the major players operating in the global vertigo treatment market.